Amgen monetizes research on osteoporosis reversal
The guest highlighted Amgen's commercialization of a novel drug discovered via research at the Stowers Institute that reverses bone decay in osteoporosis.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.